Incidence, Predictors, and Outcomes of Clinically Significant Post-ERCP Bleeding: a Contemporary Multi-center Study
Kirles Bishay,Yibing Ruan,Alan N Barkun,Yen-I Chen,Andrew Singh,Lawrence Hookey,Naveen Arya,Natalia Causada Calo,Samir C Grover,Peter D Siersema,Nirav Thosani,Saeed Darvish-Kazem,Deborah Siegal,Sydney Bass,Martin Cole,Yang Lei,Suqing Li,Rachid Mohamed,Christian Turbide,Millie Chau,Megan Howarth,Shane Cartwright,Hannah F Koury,Tamim Nashad,Zhao Wu Meng,Alejandra Tepox-Padrón,Ahmed Kayal,Emmanuel González-Moreno,Darren R Brenner,Zachary L Smith,Rajesh N Keswani,B Joseph Elmunzer,Sachin Wani,Ronald J Bridges,Robert J Hilsden,Steven J Heitman,Nauzer Forbes
DOI: https://doi.org/10.14309/ajg.0000000000002946
2024-07-05
Abstract:Background aims: Clinically significant post-endoscopic retrograde cholangiopancreatography (ERCP) bleeding (CSPEB) is common. Contemporary estimates of risk are lacking. We aimed to identify risk factors for and outcomes following CSPEB. Methods: We analyzed multi-center prospective ERCP data between 2018-2023 with 30-day follow-up. The primary outcome was CSPEB, defined as hematemesis, melena, or hematochezia resulting in: hemoglobin drop ≥20 g/L or transfusion and/or endoscopy to evaluate suspected bleeding, and/or unplanned healthcare visitation and/or prolongation of existing admission. Firth logistic regression was employed. P-values <0.05 were significant, with odds ratios (ORs) and 95% confidence intervals reported. Results: CSPEB occurred following 129 (1.5%) of 8,517 ERCPs (mean onset 3.2 days), with 110 of 4,849 events (2.3%) occurring following higher-risk interventions (sphincterotomy, sphincteroplasty, pre-cut sphincterotomy, and/or needle-knife access). CSPEB patients required endoscopy and transfusion in 86.0% and 53.5% of cases, respectively, with three cases (2.3%) being fatal. P2Y12 inhibitors were held for a median of 4 days (IQR 4) prior to higher-risk ERCP. Following higher-risk interventions, P2Y12 inhibitors (OR 3.33, 1.26-7.74), warfarin (OR 8.54, 3.32-19.81), dabigatran (OR 13.40, 2.06-59.96), rivaroxaban (OR 7.42, 3.43-15.24) and apixaban (OR 4.16, 1.99-8.20) were associated with CSPEB. Significant intraprocedural bleeding post sphincterotomy (OR 2.32, 1.06-4.60), but not post sphincteroplasty, was also associated. Concomitant cardiorespiratory events occurred more frequently within 30 days following CSPEB (OR 12.71, 4.75-32.54). Conclusions: Risks of antiplatelet-related CSPEB may be underestimated by endoscopists based on observations of suboptimal holding before higher-risk ERCP. Appropriate periprocedural antithrombotic management is essential and could represent novel quality initiative targets.